Covetrus Announces New Structure, Focus and Strength within Europe
21.12.2021 16:00:00 EET | Business Wire | Press release
Covetrus® (Nasdaq: CVET), a global leader in animal-health technology and services, today announced a new organizational structure within Northern and Central Europe to execute the company’s three-year strategy, deliver operational efficiencies, and better enable the company’s combined commercial teams to service their customers and provide a reset for the German and U.K. businesses.
Earlier this year, Covetrus announced the hiring of András Bolcskei as Covetrus’ first president of International. Mr. Bolcskei was charged with bringing all commercial teams outside of North America together, and today’s announcement advances that plan. Key changes include the development of a new International leadership team and a concerted focus within the U.K. and German businesses, an anticipated element of the company’s strategic plan, as well as an immediate and strong reaction to recent pressures within those two regions.
Covetrus Germany will move its DACH headquarter from Hamburg to Düsseldorf. Effective April 1, 2022, Covetrus’ Düsseldorf location will create the DACH hub for the company under the leadership of Dr. Andreas Tschuor and will restrengthen its commercial capabilities, service to customers and competitiveness within the German market. In addition, the proximity of Düsseldorf to two other Covetrus regions (Belgium and the Netherlands) will enable and lead to increased efficiencies and operational excellence within those regions’ commercial teams. The company will close its Hamburg office on March 31, 2022. Employment contracts tied to Hamburg will be discontinued, and employees will be offered the choice to continue employment with unchanged conditions in the new Düsseldorf office on April 1, 2022.
Development of a new leadership team to drive the company’s International Business. Effective January 1, 2022, and similar to the structure adopted in the U.S. earlier this year, the U.K. commercial and the Global Technology Solutions (GTS) teams, and the U.K. & Europe sales teams will come under one, unified commercial leadership, led by Loic Jegou, Country Manager and VP, Northern Europe. Mr. Jegou joined Covetrus last month with 18 years of experience in the animal health pharmaceutical business at Pfizer and MSD Animal Health. The U.K. business will increase service to U.K.-based customers through an extended focus of the company’s “One Face to Customer” approach. Additionally, in keeping with a true International approach, Australia and New Zealand are adopting the same go-to-market strategy, and the GTS sales team within the APAC region will report directly to Simon Hellams, VP, APAC. Covetrus is uniquely suited, within the animal health industry, to meet their customers’ overall needs with a single point of contact due to Covetrus’ expansive product and service offering and breadth of capabilities.
“These moves position Covetrus to win for our European customers and win for our global business,” said Ben Wolin, President & CEO. “I have absolute confidence in our ability to drive our strategy, win back our position within the German and U.K. markets, drive greater outcomes for our customers and the animals they care for … and drive success for all our teams and stakeholders.”
About Covetrus
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine with more than 5,500 employees serving over 100,000 customers around the globe. For more information about Covetrus visit https://covetrus.com/.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the Securities and Exchange Commission. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005247/en/
Contact information
Investor Contact
Nicholas Jansen
nicholas.jansen@covetrus.com
(207) 550-8106
Media Contact
Mona Downey
mona.downey@covetrus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom